ESMO E-Learning: NSCLC Highlights 2012 (Part 1 and 2)
- To provide an update on data from latest clinical studies in patients with non-small-cell lung cancer (NSCLC) on integration of EGFR Tyrosine kinase inhibitors (TKIs) and chemotherapy
- To provide an update on recent clinical studies on first-line EGFR TKI and biomarkers in EGFR mutation positive NSCLC patients
- To provide an update on clinical studies that tested strategies on overcoming EGFR TKI resistance in EGFR mutation positive NSCLC patients
- To provide an update on data from latest clinical studies on molecular targeting beyond EGFR in patients with non-small cell lung cancer (NSCLC)
- To provide an update on recent clinical studies on multimodal treatments for stage III NSCLC patients
- To provide an update on data from recent clinical studies on chemotherapy in patients with performance status 2 and maintenance chemotherapy, as well as early results of immunotherapy potentials in patients with advanced NSCLC
|Title||Duration||Content||CME Points||CME Test|
|NSCLC Highlights 2012 - Part 1||TBD min.||56 slides||1||Take Test|
|NSCLC Highlights 2012 - Part 2||TBD min.||61 slides||1||Take Test|
The oncology community is faced with some outstanding results from recent clinical trials in patients with non-small-cell lung cancer (NSCLC) and therefore there is the need to summarise what has been achieved, as well as elaborate on areas where the change in current practice is needed. This E-Learning module is therefore intended to summarise from the clinical perspective some of the most important results presented in NSCLC at main oncology events in 2012 and results published in prestigious scientific journals. Physicians who treat patients with NSCLC are faced with rapid advances to be implemented in the clinic and there was a strong need to come up with such module and present all important information together.
Because of the extent of the information presented, the material is divided into two parts. The first one elaborates on data from latest clinical studies in patients with NSCLC on integration of EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy, data from studies on first-line EGFR TKI and biomarkers in EGFR mutation positive patients, and strategies to overcome EGFR TKI resistance in EGFR mutation positive disease.
The second module is divided into several chapters and covers information on molecular targeting beyond EGFR (clinical studies on ALK targeting and analysis of resistance mechanisms to ALK-kinase inhibitors, clinical targeting of K-Ras and ROS1 genes), advances in multimodal treatment in patients with stage III NSCLC, advances in chemotherapy for patients with performance status 2 and advanced NSCLC, maintenance chemotherapy in patients with advanced non-squamous NSCLC, and early results of clinical activity and safety from targeting PD-1/PD-L1 pathway in patients with advanced NSCLC.
For all of those who have missed for any reason even a piece of unprecedented level of clinically relevant information from studies in NSCLC presented last year, this E-Learning module is the perfect and easiest way to keep in tune with highlights on the progress achieved.
The author has reported no conflict of interest